Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms (Vol 12, 37, 2022)

被引：0
|
作者：
Hu, Mengshi
Yang, Tao
Yang, Linyu
Niu, Lu
Zhu, Jinbing
Zhao, Ailin
Shi, Mingsong
Yuan, Xue
Tang, Minghai
Yang, Jianhong
Pei, Heying
Yang, Zhuang
Chen, Qiang
Ye, Haoyu
Niu, Ting
Chen, Lijuan
机构：
[1] West China Hospital of Sichuan University,State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics
[2] West China Hospital of Sichuan University,Department of Hematology and Research Laboratory of Hematology
[3] Chengdu Zenitar Biomedical Technology Co.,undefined
[4] Ltd,undefined
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01058-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
    Hu, Mengshi
    Yang, Tao
    Yang, Linyu
    Niu, Lu
    Zhu, Jinbing
    Zhao, Ailin
    Shi, Mingsong
    Yuan, Xue
    Tang, Minghai
    Yang, Jianhong
    Pei, Heying
    Yang, Zhuang
    Chen, Qiang
    Ye, Haoyu
    Niu, Ting
    Chen, Lijuan
    BLOOD CANCER JOURNAL, 2022, 12 (03)
  • [2] Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate
    Zhu, Jiali
    Yang, Tao
    Tang, Minghai
    Yang, Zhuang
    Pei, Heying
    Ye, Haoyu
    Tang, Yu
    Cheng, Zhixuan
    Lin, Ping
    Chen, Lijuan
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [3] R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
    Shide, Kotaro
    Kameda, Takuro
    Markovtsov, Vadim
    Shimoda, Haruko K.
    Tonkin, Elizabeth
    Fang, Shuling
    Liu, Chian
    Gelman, Marina
    Lang, Wayne
    Romero, Jason
    McLaughlin, John
    Bhamidipati, Somasekhar
    Clough, Jeffrey
    Low, Caroline
    Reitsma, Andrea
    Siu, Stacey
    Pine, Polly
    Park, Gary
    Torneros, Allan
    Duan, Matt
    Singh, Rajinder
    Payan, Donald G.
    Matsunaga, Takuya
    Hitoshi, Yasumichi
    Shimoda, Kazuya
    BLOOD, 2011, 117 (25) : 6866 - 6875
  • [4] Inhibition of SHP2 Ameliorates JAK2V617F-Induced Myeloproliferative Neoplasms
    Yang, Yue
    Le, Bao T.
    Dutta, Avik
    Mohi, Golam
    BLOOD, 2021, 138
  • [5] Pleckstrin-2 Plays an Essential Role in the Pathogenesis of JAK2V617F-Induced Myeloproliferative Neoplasms
    Zhao, Baobing
    Mei, Yang
    Sumagin, Ronen
    Yang, Jing
    Thorsheim, Chelsea
    Zhao, Liang
    Stalker, Timothy J.
    Wen, Jeremy Q.
    Crispino, John
    Abrams, Charles S.
    Ji, Peng
    BLOOD, 2016, 128 (22)
  • [6] Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
    Werning, Gerlinde
    Kharas, Michael G.
    Okabe, Rachel
    Moore, Sandra A.
    Leeman, Dena S.
    Cullen, Dana E.
    Gozo, Maricel
    McDowell, Elizabeth P.
    Levine, Ross L.
    Doukas, John
    Mak, Chi Ching
    Noronha, Glenn
    Martin, Michael
    Ko, Yon D.
    Lee, Benjamin H.
    Soll, Richard M.
    Tefferi, Ayalew
    Hood, John D.
    Gilliland, D. Gary
    CANCER CELL, 2008, 13 (04) : 311 - 320
  • [7] Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone
    Zhao, Ailin
    Wang, Xin
    Hu, Mengshi
    Chen, Lijuan
    Niu, Ting
    BLOOD, 2022, 140 : 2624 - 2625
  • [8] Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a marine model of JAK2V617F-induced polycythemia vera
    Wernig, Gerlinde
    Kharas, Michael G.
    Okabe, Rachel
    Moore, Sandra A.
    Leeman, Dena S.
    Cullen, Dana E.
    Gozo, Maricel
    McDowell, Elizabeth P.
    Levine, Ross L.
    Doukas, John
    Mak, Chi Ming
    Noronha, Glenn
    Martin, Michael
    Ko, Yon D.
    Lee, Benjamin H.
    Soll, Richard
    Tefferi, Ayalew
    Hood, John D.
    Gilliland, D. Gary
    BLOOD, 2007, 110 (11) : 171A - 171A
  • [9] A GERMLINE JAK2 SNP IS ASSOCIATED WITH PREDISPOSITION TO THE DEVELOPMENT OF JAK2 V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS
    Kilpivaara, M.
    Mukherjee, S.
    Schram, M.
    Wadleigh, M.
    Mullally, A.
    Ebert, L.
    Bass, A.
    Marubayashi, S.
    Heguy, A.
    Garcia-Manero, G.
    Kantarjian, H.
    Offit, K.
    Stone, M.
    Gilliland, D.
    Klein, J.
    Levine, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 420 - 420
  • [10] JAK2 V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms
    Choi, Daniel C.
    Abu-Zeinah, Ghaith
    Kermani, Pouneh
    Messali, Nassima
    Yabut, Maria Mia
    Erdos, Katie
    Scandura, Joseph M.
    BLOOD, 2023, 142
12345